Drugs / YH32364
last change Jun 2025 re-read 3 minutes ago

YH32364

targets EGFR via inhibition

Developed for
metastatic neoplasm
Investigated by
Yuhan Corporation

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06975410 Jun 2025 → Jun 2027 expected metastatic neoplasm Yuhan Corporation Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as YH32364 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975410 ↗
Action Inhibit “It also helps block EGFR signals” NCT06975410 ↗
Route Intravenous “administered via intravenous (IV) infusion once every two weeks” NCT06975410 ↗
Target EGFR “targets both Epidermal Growth Factor Receptor (EGFR) and 4-1BB” NCT06975410 ↗